OtherArticle
Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Pablo Aviles, Raquel Altares, Lotte van Andel, Rubin Lubomirov, Salvador Fudio, Hilde Rosing, Francisco M Marquez del Pino, Matthijs M Tibben, Gonzalo Benedit, Lianda Nan-Offeringa, Xarles Erik Luepke Estefan, Andres Francesch, Ali Zeaiter, Carmen Cuevas, Jan H.M. Schellens and Jos H. Beijnen
Drug Metabolism and Disposition January 18, 2022, DMD-AR-2021-000668; DOI: https://doi.org/10.1124/dmd.121.000668
Pablo Aviles
1R&D, PharmaMar S.A., Spain
Raquel Altares
1R&D, PharmaMar S.A., Spain
Lotte van Andel
2TNO, Netherlands
Rubin Lubomirov
1R&D, PharmaMar S.A., Spain
Salvador Fudio
1R&D, PharmaMar S.A., Spain
Hilde Rosing
3Antoni van Leewenhoek Hospital, The Netherlands Cancer Institute, Netherlands
Francisco M Marquez del Pino
1R&D, PharmaMar S.A., Spain
Matthijs M Tibben
3Antoni van Leewenhoek Hospital, The Netherlands Cancer Institute, Netherlands
Gonzalo Benedit
1R&D, PharmaMar S.A., Spain
Lianda Nan-Offeringa
3Antoni van Leewenhoek Hospital, The Netherlands Cancer Institute, Netherlands
Xarles Erik Luepke Estefan
1R&D, PharmaMar S.A., Spain
Andres Francesch
1R&D, PharmaMar S.A., Spain
Ali Zeaiter
1R&D, PharmaMar S.A., Spain
Carmen Cuevas
1R&D, PharmaMar S.A., Spain
Jan H.M. Schellens
4Utrech University, Netherlands
Jos H. Beijnen
5The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Netherlands
Jump to comment:
No eLetters have been published for this article.
In this issue
OtherArticle
ADME of lurbinectedin in nonclinical species and patients.
Pablo Aviles, Raquel Altares, Lotte van Andel, Rubin Lubomirov, Salvador Fudio, Hilde Rosing, Francisco M Marquez del Pino, Matthijs M Tibben, Gonzalo Benedit, Lianda Nan-Offeringa, Xarles Erik Luepke Estefan, Andres Francesch, Ali Zeaiter, Carmen Cuevas, Jan H.M. Schellens and Jos H. Beijnen
Drug Metabolism and Disposition January 18, 2022, DMD-AR-2021-000668; DOI: https://doi.org/10.1124/dmd.121.000668
OtherArticle
ADME of lurbinectedin in nonclinical species and patients.
Pablo Aviles, Raquel Altares, Lotte van Andel, Rubin Lubomirov, Salvador Fudio, Hilde Rosing, Francisco M Marquez del Pino, Matthijs M Tibben, Gonzalo Benedit, Lianda Nan-Offeringa, Xarles Erik Luepke Estefan, Andres Francesch, Ali Zeaiter, Carmen Cuevas, Jan H.M. Schellens and Jos H. Beijnen
Drug Metabolism and Disposition January 18, 2022, DMD-AR-2021-000668; DOI: https://doi.org/10.1124/dmd.121.000668
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement